Advancements in genomic medicine are transforming how we approach hereditary breast cancer genetics. However, most reference data still originates from European and North American populations. Consequently, this creates a significant gap in variant interpretation for underrepresented groups, including those in Latin America and India. A recent Chilean study addresses this disparity by utilizing whole-exome sequencing (WES) to provide a more comprehensive view of the germline variant spectrum.

The Value of Extended Panels in Hereditary Breast Cancer Genetics

The research included 140 patients with clinically suspected hereditary breast cancer. By performing WES, the team analyzed both canonical predisposition genes and an extended set of cancer susceptibility markers. Importantly, this expanded analysis increased the detection of pathogenic and likely pathogenic variants from 18% to 24%. While BRCA1 and BRCA2 remained the most common sites for mutations, truncating variants were the predominant alteration type across the cohort.

Furthermore, these findings emphasize that traditional gene panels might overlook a significant portion of patients. For instance, Indian studies have also reported high mutation frequencies that differ from Western cohorts. Therefore, incorporating population-specific genomic data is essential for equitable implementation of genomic medicine.

Clinical Implications for Underrepresented Populations

Improving variant interpretation directly impacts clinical decision-making. Specifically, the Chilean study demonstrated that expanded gene analysis reduces the proportion of patients receiving negative genetic results. This shift allows for more personalized risk assessments and tailored treatment plans. Similarly, in India, where the breast cancer burden is high among younger women, tailored approaches to screening and treatment are vital for improving survival rates.

Frequently Asked Questions

Why is population-specific data critical for hereditary breast cancer genetics?

Genetic diversity across different ethnicities means that a variant classified as benign in one population might be pathogenic in another. Population-specific data helps clinicians accurately interpret these variants, ensuring that patients from underrepresented regions receive precise risk assessments.

How does whole-exome sequencing improve diagnostic yield?

Whole-exome sequencing scans a broader range of the genome compared to standard panels. This allows for the detection of variants in non-canonical genes that may still contribute significantly to cancer susceptibility, as evidenced by the 6% increase in detection seen in the Chilean study.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a substitute for professional healthcare. Always consult with a qualified physician for diagnosis and treatment. Refer to the latest local and national guidelines for clinical practice.

References

Morales-González S et al. Broad germline variant spectrum revealed by whole-exome sequencing in an underrepresented Latin American population with hereditary breast cancer. Hum Genomics. 2026 May 14. doi: 10.1186/s40246-026-00983-2. PMID: 42135811.

Saini S et al. Understanding the genetic epidemiology of hereditary breast cancer in India using whole genome data from 1029 healthy individuals. J Cancer Epidemiol. 2025. PMID: 40024972.

Gulzar et al. High Prevalence of BRCA Mutations in Indian Breast Cancer Patients: Insights from a Diagnostic Lab. J Med Hum Genet. 2024. doi: 10.1186/s43042-024-00567-6.